These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 11114136

  • 1. Bone marrow aspirate on the 14th day of induction treatment as a prognostic tool in de novo adult acute myeloid leukemia.
    Liso V, Albano F, Pastore D, Carluccio P, Mele G, Lamacchia M, Mestice A, Specchia G.
    Haematologica; 2000 Dec; 85(12):1285-90. PubMed ID: 11114136
    [Abstract] [Full Text] [Related]

  • 2. [The prognostic significance of regular bone marrow aspirations during induction chemotherapy in acute myeloid leukemia].
    Mi Y, Bian S, Xue Y, Zhao Y, Meng Q, Guo Y, Li R, Qin T.
    Zhonghua Xue Ye Xue Za Zhi; 1997 Jun; 18(6):305-7. PubMed ID: 15622625
    [Abstract] [Full Text] [Related]

  • 3. Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia.
    Hussein K, Jahagirdar B, Gupta P, Burns L, Larsen K, Weisdorf D.
    Am J Hematol; 2008 Jun; 83(6):446-50. PubMed ID: 18247382
    [Abstract] [Full Text] [Related]

  • 4. A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group.
    Haferlach T, Kern W, Schoch C, Schnittger S, Sauerland MC, Heinecke A, Büchner T, Hiddemann W, German AML Cooperative Group.
    Haematologica; 2004 Apr; 89(4):408-18. PubMed ID: 15075074
    [Abstract] [Full Text] [Related]

  • 5. [Prognostic value of early treatment response in children with acute myeloid leukemia].
    Tie LJ, Gu LJ, Song DL, Xue HL, Tang JY, Dong L, Pan C, Chen J, Ye H, Chen J, Wang YP, Zou JY.
    Zhonghua Yi Xue Za Zhi; 2006 Jul 11; 86(26):1837-40. PubMed ID: 17054861
    [Abstract] [Full Text] [Related]

  • 6. CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome.
    Raspadori D, Damiani D, Michieli M, Stocchi R, Gentili S, Gozzetti A, Masolini P, Michelutti A, Geromin A, Fanin R, Lauria F.
    Haematologica; 2002 Nov 11; 87(11):1135-40. PubMed ID: 12414342
    [Abstract] [Full Text] [Related]

  • 7. Dysmegakaryopoiesis predicting response to therapy in acute myeloid leukaemia. A histologic and clinical study.
    Delacrétaz F, Spertini O, Schmidt PM, Grob JP.
    Pathol Res Pract; 1991 Mar 11; 187(2-3):290-5. PubMed ID: 2068013
    [Abstract] [Full Text] [Related]

  • 8. Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study.
    Behringer B, Pitako JA, Kunzmann R, Schmoor C, Behringer D, Mertelsmann R, Lübbert M.
    Ann Hematol; 2003 Jul 11; 82(7):381-9. PubMed ID: 12756497
    [Abstract] [Full Text] [Related]

  • 9. Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study.
    Gianfaldoni G, Mannelli F, Baccini M, Antonioli E, Leoni F, Bosi A.
    Br J Haematol; 2006 Jul 11; 134(1):54-7. PubMed ID: 16803567
    [Abstract] [Full Text] [Related]

  • 10. [Effectiveness analysis of HA based triple-drug regimen as induction chemotherapy in the treatment of acute myeloid leukemia and its relationship with karyotype].
    Mi YC, Xue YP, Yu WJ, Liu SH, Zhao YZ, Meng QX, Bian SG, Wang JX.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Dec 11; 26(12):705-9. PubMed ID: 16620570
    [Abstract] [Full Text] [Related]

  • 11. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups.
    Schoch C, Kern W, Schnittger S, Büchner T, Hiddemann W, Haferlach T.
    Haematologica; 2004 Sep 11; 89(9):1082-90. PubMed ID: 15377469
    [Abstract] [Full Text] [Related]

  • 12. Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol.
    Oriol A, Ribera JM, Esteve J, Guàrdia R, Brunet S, Bueno J, Pedro C, Llorente A, Tormo M, Besalduch J, Sánchez JM, Batlle M, Vivancos P, Carreras E, Vilà JM, Julià A, Sierra J, Montserrat E, Feliu E, CETLAM AML-99.
    Haematologica; 2004 Jul 11; 89(7):791-800. PubMed ID: 15257930
    [Abstract] [Full Text] [Related]

  • 13. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
    Liu J, Mi Y, Fu M, Yu W, Wang Y, Lin D, Bian S, Wang J.
    Am J Hematol; 2009 Jul 11; 84(7):422-7. PubMed ID: 19484734
    [Abstract] [Full Text] [Related]

  • 14. Quantitation of minimal residual disease in acute myeloid leukemia by tryptase monitoring identifies a group of patients with a high risk of relapse.
    Sperr WR, Mitterbauer M, Mitterbauer G, Kundi M, Jäger U, Lechner K, Valent P.
    Clin Cancer Res; 2005 Sep 15; 11(18):6536-43. PubMed ID: 16166430
    [Abstract] [Full Text] [Related]

  • 15. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
    Niparuck P, Chuncharunee S, Ungkanont A, Udomtrupayakul U, Aungchaisuksiri P, Rerkamnuatchoke B, Jootar S, Atichartakarn V.
    J Med Assoc Thai; 2009 Sep 15; 92(9):1143-9. PubMed ID: 19772172
    [Abstract] [Full Text] [Related]

  • 16. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D, Chelghoum Y, Le QH, Elhamri M, Michallet M, Thomas X.
    Ann Hematol; 2003 Nov 15; 82(11):684-90. PubMed ID: 12928754
    [Abstract] [Full Text] [Related]

  • 17. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
    Ribera JM, Ortega JJ, Oriol A, Granada I, Hernández-Rivas JM, Parody R, Bethencourt C, Rivas C, Bastida P, del Potro E, González-Valentín ME, Moreno MJ, Besalduch J, Fernández-Calvo J, Tormo M, Arias J, Molinés A, Sanz MA, Maldonado J, Millá F, Feliu E, San Miguel JF, PETHEMA Group, Spanish Society of Hematology.
    Haematologica; 2002 Feb 15; 87(2):154-66. PubMed ID: 11836166
    [Abstract] [Full Text] [Related]

  • 18. Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia: potential effector cells for immunotherapy?
    Aswald JM, Wang XH, Aswald S, Lutynski A, Minden MD, Messner HA, Keating A.
    Cytometry B Clin Cytom; 2006 Nov 15; 70(6):379-90. PubMed ID: 16977635
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Analysis of prognostic variables in childhood acute myeloid leukemia].
    Gu LJ, Tie LJ, Xue HL, Tang JY, Chen J, Pan C, Chen J, Ye H, Wang YP, Dong L.
    Zhonghua Xue Ye Xue Za Zhi; 2006 Jan 15; 27(1):10-3. PubMed ID: 16732931
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.